The boundaries of "women's health" investing are widening in directions that would have seemed unlikely a few years ago.
Women’s health in 2026 covers a noticeably broader range of startups than the category's early cohort of period-tracking apps, and the funding data increasingly reflects that.
A definition stretched by a single round
Contraline raised a $92.5M Series B in June 2026, co-led by BVF Partners and RA Capital Management, with participation from GV, Lumira Ventures and Invus, to advance NES/T, a once-daily reversible hormonal male contraceptive gel, into Phase 3 development.
In the same funding tracker, Wavelet Medical raised a $7M seed round for AI-powered fetal brain monitoring, and an oncology diagnostics startup closed a Series A of up to $30M for a blood-based cancer test, both filed under the same women's health investment umbrella that Contraline sits within.
For scale, the broader women’s health investor base now includes more than 40 active VCs, and category leaders elsewhere in women's health carry substantial cumulative totals of their own: Maven Clinic has raised $417.1M to date, Kindbody $306.3M, and UK-based Flo Health $275.8M, giving a sense of how much larger the overall capital base has become even as a single male contraceptive round grabs this month's headline.
A wider investor base for everyone else too
A male contraceptive startup raising nearly $100M in a single round shows how far women's health investing has stretched beyond its original, narrower definition.
That widening definition changes who the natural investor and partner base looks like. Categories like male contraception pull in specialist biotech investors who might not otherwise evaluate a women's health deal, expanding the overall pool of capital available to startups across the wider ecosystem.
That includes the more traditional fertility and menopause platforms discussed elsewhere in this issue, which don't naturally attract that same specialist biotech investor base on their own, but benefit from being adjacent to a category now drawing broader attention.
Whether the definition survives a tighter market
Watch whether this broader definition holds through the next funding cycle, or whether investors start drawing sharper lines between core reproductive health and adjacent categories once capital becomes more selective, which is typically when investor definitions narrow back toward the original thesis.
Also watch whether more male-focused reproductive health startups follow Contraline's lead in courting the same investor base, or whether this round proves to be an outlier rather than the start of a pattern.
